Imperial College London

#Aging Cell #Cellular stress #Francis Crick Institute #Imperial College London #Medical research #Medical Research Council #MRC Laboratory of Medical Sciences #Queen Mary University of London #University of Cologne #University of Lyon

Drug extends animal life by activating ‘energy saver’ mode 

Scientists have successfully used a drug to prolong the lifespan of several species of animals, in some cases by more than 25%.  The study, published in Aging Cell, found strong evidence that triggering a protein, governing energy levels, may help organisms live significantly longer. … Read More

#News

Heart attack patient with doctor
#Cardiovascular disease #Cholesterol #Heart attack #Imperial College London #Lund University #Statins

Statins and ezetimibe combination could prevent heart attacks

A new study from researchers at Lund University in Sweden and Imperial College London suggests that treating patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks.  For those who survive a heart attack, the risk of a… Read More

#News

Child with cystic fibrosis on ventilator
#Boehringer Ingelheim #Cystic fibrosis #Gene therapy #Imperial College London #Phase II trial

Inhaled gene therapy for cystic fibrosis enters the clinic

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and OXB have announced the start of LENTICLAIR 1, a Phase I/II trial of gene therapy BI 3720931.  The therapy has been designed to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene… Read More

#News

AI clinical trials concept
#Antimicrobial resistance (AMR) #Artificial intelligence (AI) #Google #Imperial College London

AI co-scientist could supercharge science, say researchers

A complex problem that took scientists a decade to explain was solved in just two days by a new artificial intelligence (AI) tool, the BBC has reported.  Professor José Penadés and his team at from the Imperial College London Department of Infectious Disease had spent 10 years… Read More

#News #Trending News

Laboratory mouse
#Ageing #Antibody #Duke-NUS Medical School #Healthspan #Imperial College London #Medical Research Council Laboratory of Medical Science #Mouse models

Anti-IL-11 drug extends lifespan by over 20% in mice

Scientists have discovered that ‘switching off’ protein interleukin 11 (IL-11) can significantly increase the healthy lifespan of mice by almost 25%. The scientists at the Medical Research Council Laboratory of Medical Science (MRC LMS) and Imperial College London, working with colleagues at Duke-NUS Medical School in… Read More

#Editor's Choice #News

Natural killer cells
#Cell therapy #Imperial College London #Interview #Natural killer cells #NK:IO #Oncology

Natural born killers: University spinout turns NK cell therapy into business

Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. Diana Spencer catches up with Co-Founder Mike Romanos to find out more. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? MR:  Cancer… Read More

#Cancer Research #Exclusive Content #Opinion #Start-up Zone

#Antibody drug conjugate (ADC) #Financing #Francis Crick Institute #Imperial College London #Myricx Bio #Start-ups

Myricx Bio announces £90m ($114m) Series A financing

UK biotech Myricx Bio has raised £90 ($114) million Series A financing to support the development of its N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) therapeutics. The round was co-led by new investors Novo Holdings and Abingworth, with additional support from British Patient Capital, Cancer Research Horizons and Eli Lilly, plus… Read More

#Business & Investment #News #Trending News

Vaccine vial and syringe
#Cancer vaccine #Imperial College London #Moderna #mRNA-based vaccines #Oncology #Phase I trial

First UK patients receive experimental mRNA therapy for cancer

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The Mobilize trial is run in partnership between Imperial College London and… Read More

#Cancer Research #News #Trending News

Luchen Li, wearing the sensor suit, and Professor Aldo Faisal.
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trials #Imperial College London #Movement disorders #Rare disease #Wearable tech

AI and wearable tech could speed up drug development

A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.   By combining human movement data gathered from wearable tech with a powerful new medical AI technology, the team were able to significantly increase the efficiency… Read More

#News